DRD2 and small cell lung carcinoma: Recently, Kayum Alam and colleagues demonstrated that D2R agonists sensitize chemotherapy-resistant neuroendocrine tumors to cisplatin and etoposide, reducing tumor angiogenesis in multiple in vivo xenograft models of human small cell lung cancer (SCLC) [174].